Abstract

Major drawbacks associated with in vitro assays for sensitivity of brain tumors to specific chemotherapeutic drugs include uncertainty of end-point validity, the need for large tissue samples, and cost. Furthermore, these assays do not address the question of conversion of the drug to active moeities by metabolic pathways in the host or alteration of drug activity by binding to plasma protein. We propose to develop a technique for growth and quantitation of tumor cells in small-pore diffusion chambers that contain the tumor cells and protect them from the immune system of the immunologically unrelated host. These chambers, fabricated from acrylic rings and membranes of 0.22 μm pore size, are sterilized, filled with a precisely quantitated inoculum of tumor cells, and implanted in the peritoneal cavity of rats. Replication of the cells is determined by enzymatic digestion of the supporting matrix of the cells within the chamber and counting the single cell suspension with a hemocytometer or automated cell counter. Precise comparison can thus be made between different drugs regarding their effect on cell growth in the host. This assay can be performed with the basic equipment and personnel available in most cell culture laboratories and requires a small number of tumor cells. Mass production of the diffusion chambers may make the assay less costly and faster than assays that do not involve exposure of tumor to drug in a living host. In addition, the assay should permit screening of new chemotherapeutic agents against human tumors under physiologic conditions.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.